Respiratory medicine · 2026
People with cystic fibrosis' experience of symptom burden while taking elexacaftor/tezacaftor/ivacaftor.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Muther Emily F, Gibson Sidney L, Ford Christine, Duncan Christina, Riekert Kristin A, Lyons Emma, Hoppe Jordana E, Prickett Michelle, Isenburg Megan von, Everhart Robin S
Аннотация
BACKGROUND: Despite improvements seen with elexacaftor/tezacaftor/ivacaftor (ETI), many people with CF (PWCF) still experience symptom burden. This study aimed to evaluate current perceived symptom burden and contrast it with PWCF's recollection of symptoms before starting ETI.
METHODS: Participants were 367 PWCF, ages 7-74 years (M age = 26.2), in the "Your ETI" (yETI) study. PWCF or caregivers of children (7-12 years) completed the Change in Perceptions of Health on ETI (CHETI) survey which assessed how often they were bothered by symptoms (respiratory, gastrointestinal/nutrition, sinus/pain, sleep/fatigue, and mental health/cognitive symptoms) before starting ETI and in the past month. A change score was calculated and categorized as less bothered, stable, or more bothered. Age differences were investigated.
RESULTS: Participants were on ETI for an average of 3.9 years. A notable percentage reported being less bothered by respiratory symptoms including cough (72%) and chest tightness (66%), and gastrointestinal symptoms including stomach pain/discomfort (48%), constipation, gas, bloating (46%), and difficulty gaining weight (51%). A smaller proportion indicated more bother related to weight gain (26%), increased appetite (23%), sleep difficulties (17%), and mental health/cognitive symptoms (14-22%). Participants reported the most current bother from constipation/gas/bloating (48%), anxiety (44%), sleep difficulties (44%), and anger/irritability (43%). Adults, notably those >36 years old, typically reported these symptoms more burdensome.
CONCLUSIONS: While PWCF were bothered less by symptoms now compared to before starting ETI, some symptoms still caused a high degree of bother, particularly among 'older' adults with CF. Findings underscore the need for ongoing strategies to monitor and manage non-respiratory symptoms.
METHODS: Participants were 367 PWCF, ages 7-74 years (M age = 26.2), in the "Your ETI" (yETI) study. PWCF or caregivers of children (7-12 years) completed the Change in Perceptions of Health on ETI (CHETI) survey which assessed how often they were bothered by symptoms (respiratory, gastrointestinal/nutrition, sinus/pain, sleep/fatigue, and mental health/cognitive symptoms) before starting ETI and in the past month. A change score was calculated and categorized as less bothered, stable, or more bothered. Age differences were investigated.
RESULTS: Participants were on ETI for an average of 3.9 years. A notable percentage reported being less bothered by respiratory symptoms including cough (72%) and chest tightness (66%), and gastrointestinal symptoms including stomach pain/discomfort (48%), constipation, gas, bloating (46%), and difficulty gaining weight (51%). A smaller proportion indicated more bother related to weight gain (26%), increased appetite (23%), sleep difficulties (17%), and mental health/cognitive symptoms (14-22%). Participants reported the most current bother from constipation/gas/bloating (48%), anxiety (44%), sleep difficulties (44%), and anger/irritability (43%). Adults, notably those >36 years old, typically reported these symptoms more burdensome.
CONCLUSIONS: While PWCF were bothered less by symptoms now compared to before starting ETI, some symptoms still caused a high degree of bother, particularly among 'older' adults with CF. Findings underscore the need for ongoing strategies to monitor and manage non-respiratory symptoms.